▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #27 by analyst upside · 2026-08-12
GOSS
Gossamer Bio, Inc.
Healthcare · Market Cap $89M · P/E 0x
ANALYST PRICE TARGET
+2021.0%
implied upside to consensus target
Current Price $0.18
Consensus Target $3.86
Bull Target $15.0
Bear Target $0.28
Analysts Covering 5
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
1
Hold
2
Sell
1
52-Week Low $0.11
52-Week High $3.87
YTD Return -93.7%
FUNDAMENTALS
Market Cap $89M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.79
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $56M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.11
52-Week High $3.87
Current Price $0.18
Bear Target $0.28
Bull Target $15.0
● Now $0.18 ● Target $3.86
TRADING DATA
Avg Volume 25.9M
YTD Return -93.7%
Analyst Count 5
Consensus Hold
Upside to Target +2021.0%
Last Updated 2026-08-12

ANALYST SUMMARY

Gossamer Bio, Inc. (GOSS) is currently trading at $0.18 with a Wall Street consensus price target of $3.86, implying potential upside of 2021.0% over the next 12 months. 5 analysts currently cover GOSS, with a consensus rating of Hold - 40% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $15.0, while the most cautious has a target of $0.28.

GOSS operates in the Healthcare sector with a market capitalisation of $89M. The stock is down 93.7% year-to-date and is currently trading near the lower end of its 52-week range of $0.11 – $3.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

OSRH +2490.7%
OSR Health, Inc.
$14M · P/E 12.9x · Buy
ETST +996.5%
Earth Science Tech, Inc.
$26M · P/E 9.1x · Hold
PSTV +830.2%
Plus Therapeutics Inc
$27M · P/E 0.2x · Buy
GRI +854.5%
GRI Bio, Inc.
$4M · P/E 0.1x · Buy
DWTX +660.9%
Dogwood Therapeutics, Inc.
$62M · P/E 1.6x · Strong Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for GOSS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-05-26 31% win rate (48 calls)
Barclays - Reiterated
Underweight → Underweight 2026-05-19 Building track record
Cantor Fitzgerald ↓ Downgrade
Overweight → Neutral 2026-03-23 40% win rate (10 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-06 31% win rate (48 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-03-05 14% win rate (7 calls)
Wedbush ↓ Downgrade
Outperform → Neutral 2026-02-24 Building track record
Barclays ↓ Downgrade
Overweight → Underweight 2026-02-24 Building track record
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2026-02-24 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
21
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →